<DOC>
	<DOC>NCT00437619</DOC>
	<brief_summary>This single arm study will evaluate the efficacy and safety of sequential treatment with Diavobet (betamethasone propionate 0.5mg/g plus calcipotriol hydrate 50 micrograms/g) once daily for 4 weeks followed by Daivonex (calcipotriol hydrate 50 micrograms/g) twice daily for 4 weeks, in the control of signs and symptoms in patients with mild to moderate psoriasis. Only patients showing a &gt;50% response to Daivobet will progress to the Daivonex maintenance phase. The anticipated time on study treatment is &lt;3 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>adult patients &gt;=18 years of age; clinical diagnosis of psoriasis vulgaris; PASI score 112 in &gt;=1 body area. clinical presentation of erythrodermic pustular psoriasis, expressed in plates and localized lesions on face and/or scalp; viral, fungal or bacterial skin infections; use of any topical treatment for psoriasis within previous 15 days; use of any systemic therapy and phototherapy for psoriasis within previous 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>